Apimeds Pharmaceuticals US Cash Flow Statement (2023-2025) | APUS

Cash Flow Statement Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Operating Activities
Net Income (Quarter) -0.30M-0.45M-0.33M-0.31M-0.40M-2.67M-1.79M-7.22M
Depreciation and Depletion (Quarter) 0.00M0.00M
Share-based Compensation (Quarter) 0.18M0.04M1.81M
Gains from Investment Securities (Quarter) 0.21M0.21M-0.01M-0.01M2.02M
Non-cash Items (Quarter) 0.21M0.36M0.37M0.43M
Cash from Operations (Quarter) -0.26M-0.18M-0.19M-0.10M-0.02M-3.36M-1.73M-3.82M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter) 0.02M0.01M0.02M0.06M0.03M0.01M1.000.24M
Depreciation & Amortization (CF) (Quarter) 0.00M0.00M
Change in Working Capital
Change in Accured Expenses (Quarter) 0.01M0.24M0.11M0.18M0.34M-0.82M0.45M
Other Working Capital Changes (Quarter) -0.00M-1.00-734.00-40.001.79M0.43M0.19M
Investing Activities
Capital Expenditures (Quarter) 0.02M0.02M
Cash from Investing Activities (Quarter) -0.02M-10.02M
Financing Activities
Other financing activities (Quarter) 1.70M
Cash from Financing Activities (Quarter) 0.15M0.08M0.27M11.86M8.49M
Additional items
Change in Cash (Quarter) -0.26M-0.08M-0.04M-0.02M0.25M8.48M-1.75M-5.35M
Beginning Cash Balance (Quarter) 0.25M
Free Cash Flow (Quarter) -0.26M-0.18M-0.19M-0.10M-0.02M-3.36M-1.75M-3.84M
Net Cash Flow (Quarter) -0.26M-0.18M-0.04M-0.02M0.25M8.50M-1.75M-5.35M